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EVALUATION OF SCLEROSTIN LEVELS IN PATIENTS SUFFERING 
FROM CHRONIC KIDNEY DISEASES
Background: Sclerostin (Sost) is a new promising bone marker. Indeed, it inhibits 
bone formation by regulating osteoblast function and promoting osteoblast
apoptosis. Sclerostin also antagonises osteoblast diffentiation by blocking the Wnt-
pathway. Finally, sclerostin is produced by the osteocytes and could be a new 
therapeutical target for vascular calcification. However, little is known about 
sclerostin in patients suffering from chronic kidney diseases (CKD). In this study, we 
aimed to correlate sclerostin levels with different bone markers in stage 3 and 4 
CKD patients.
Methods: We used the remnant serum of 77 stage 3 and 4 non renal-transplanted 
patients (64.4±13.5 yo; 46 female) to determine sclerostin levels with 2 different 
Elisas:
-Quidel Corporation, Santa Clara, CA 
-Biomedica, Vienna, Austria). 
N-terminal propetide of type 1 collagen (P1NP), C-terminal telopeptides of type1 
collagen (CTX) and intact PTH (iPTH) levels were determined with the IDS iSYS
(IDS, Boldon, UK). Creatinine (enzymatic, IDMS traceable), calcium and 
phosphorus levels were determined on Roche Modular (Roche, Mannheim, 
Germany) and the estimation of glomerular filtration rate (eGFR) was achieved 
with the MDRD formula.
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Results: No correlation was observed between sclerostin levels and the 
different bone markers or iPTH. Sclerostin levels were not influenced by the 
glomerular filtration rate. The 5th and 95th percentiles observed with 
respectively the Quidel and the Biomedica assays were 0.38 – 1.50 and 0.34 –
2.17 pg/mL, respectively. 











































y = 0,59 x + 0,15
Discussion: In this study, we showed for the first time that sclerostin levels 
were not influenced by renal deficiency. We also showed, that, contrary to 
other studied populations, like patients presenting disorders of the parathyroid 
gland (Costa AG, JCEM 2011) or type 2 diabetes (Garcia-Martin A, JCEM 
2012), sclerostin levels were not associated with bone formation or resorption
markers.
Conclusions: As it is not influenced by the GFR, sclerostin could be a new 
marker of choice for the exploration of CKD-Mineral bone disease and 
vascular calcifications. The lack of correlation with the traditional bone 
markers in CKD patients is intriguing and, if confirmed in larger studies, opens 
a new field of research (the osteocyte function) in these patients. Finally, the 
Quidel and Biomedica assays give similar results, even if a standardisation is 
needed.
